Ganciclovir Ophthalmic

Ganciclovir Ophthalmic is filed as Ophthalmic Antiviral. The sections below restate public label fields stored for this profile.

Class
Ophthalmic Antiviral
Route
INTRAVENOUS
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Ganciclovir Ophthalmic Gel contains 0.15% of ganciclovir in a sterile preserved topical ophthalmic gel. Ganciclovir Ophthalmic Gel contains 0.15% of ganciclovir in a sterile preserved topical ophthalmic gel. ( 3 )
Manufacturer
Endo USA, Inc.
Boxed warning
Yes

Approved uses

1 INDICATIONS AND USAGE Ganciclovir Ophthalmic Gel 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). Ganciclovir Ophthalmic Gel is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). ( 1 )

How it works

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ganciclovir Ophthalmic Gel 0.15% contains the active ingredient, ganciclovir, which is a guanosine derivative that, upon phosphorylation, inhibits DNA replication by herpes simplex viruses (HSV). Ganciclovir is transformed by viral and cellular thymidine kinases (TK) to ganciclovir triphosphate, which works as an antiviral agent by inhibiting the synthesis of viral DNA in 2 ways: competitive inhibition of viral DNA-polymerase and direct incorporation into viral primer strand DNA, resulting in DNA chain termination and prevention of replication. 12.3 Pharmacokinetics The estimated maximum daily dose of ganciclovir administered as 1 drop, 5 times per day is 0.375 mg. Compared to maintenance doses of systemically administered ganciclovir of 900 mg (oral valganciclovir) and 5 mg/kg (IV ganciclovir), the ophthalmically administered daily dose is approximately 0.04% and 0.1% of the oral dose and IV doses, respectively, thus minimal systemic exposure is expected.

Boxed warning

WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir [see Warnings and Precautions (5.1) ]. Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females [see Warnings and Precautions (5.3) ]. Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans [see Warnings and Precautions (5.4) ]. Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancers in humans [see Warnings and Precautions (5.5) ]. WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS See full prescribing information for complete boxed warning. Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir. ( 5.1 ) Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females. ( 5.3 ) Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans. ( 5.4 ) Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancer in humans. ( 5.5 )

Warnings and precautions

BOXED WARNING: WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir [see Warnings and Precautions (5.1) ]. Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females [see Warnings and Precautions (5.3) ]. Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans [see Warnings and Precautions (5.4) ]. Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancers in humans [see Warnings and Precautions (5.5) ]. WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS See full prescribing information for complete boxed warning. Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir. ( 5.1 ) Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females. ( 5.3 ) Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans. ( 5.4 ) Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancer in humans. ( 5.5 )

Contraindications

4 CONTRAINDICATIONS None. None.

Common side effects

Reported in patients were blurred vision (60%); Eye irritation (20%); Punctate keratitis (5%); And conjunctival hyperemia (5%)

Adverse reactions

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: • Hematologic Toxicity [see Warnings and Precautions ( 5.1 )] • Renal Impairment [see Warnings and Precautions ( 5.2 )] • Impairment of Fertility [see Warnings and Precautions ( 5.3 )] • Fetal Toxicity [see Warnings and Precautions ( 5.4 )] • Mutagenesis and Carcinogenesis [see Warnings and Precautions ( 5.5 )]

Dosage and administration

2 DOSAGE AND ADMINISTRATION The recommended dosing regimen for Ganciclovir Ophthalmic Gel is 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days. The recommended dosing regimen for Ganciclovir Ophthalmic Gel is 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days. ( 2 )

Drug interactions

Drug-drug interaction studies were conducted in patients with normal renal function. Patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug following concomitant administration of Ganciclovir for Injection and drugs excreted by the same pathway as ganciclovir. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug. Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 6 [see Clinical Pharmacology ( 12.3 )] . Table 6. Established and Other Potentially Significant Drug Interactions with Ganciclovir for Injection Name of the Concomitant Drug Change in the Concentration of Ganciclovir or Concomitant Drug Clinical Comment Imipenem-cilastatin Unknown Coadministration with imipenem-cilastatin is not recommended because generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. Cyclosporine or amphotericin B Unknown Monitor renal function when Ganciclovir is coadministered with cyclosporine or amphotericin B because of potential increase in serum creatinine [see Warnings and Precautions ( 5.2 )]. Mycophenolate mofetil (MMF) ↔ Ganciclovir (in patients with normal renal function) ↔ MMF (in patients with normal renal function) Based on increased risk, patients should be monitored for hematological and renal toxicity. Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged to outweigh the risks. Didanosine ↔ Ganciclovir ↑ Didanosine Patients should be closely monitored for didanosine toxicity (e.g., pancreatitis). Probenecid ↑Ganciclovir Ganciclovir for Injection dose may need to be reduced. Monitor for evidence of ganciclovir toxicity.

Common questions

What is Ganciclovir Ophthalmic approved to treat?

According to its FDA label, Ganciclovir Ophthalmic is approved for: 1 INDICATIONS AND USAGE Ganciclovir Ophthalmic Gel 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). Ganciclovir Ophthalmic Gel is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Ganciclovir Ophthalmic?

Ganciclovir Ophthalmic belongs to the Ophthalmic Antiviral class of medications.

What form does Ganciclovir Ophthalmic come in?

The FDA label lists Ganciclovir Ophthalmic as: 3 DOSAGE FORMS AND STRENGTHS Ganciclovir Ophthalmic Gel contains 0.15% of ganciclovir in a sterile preserved topical ophthalmic gel. Ganciclovir Ophthalmic Gel contains 0.15% of ganciclovir in a sterile preserved topical ophthalmic gel. ( 3 ); intravenous route. Available strengths and packaging vary by manufacturer.

Does Ganciclovir Ophthalmic have a Boxed Warning?

Yes. The FDA label for Ganciclovir Ophthalmic carries a Boxed Warning. Excerpt: "WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients tre…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Ganciclovir Ophthalmic cost?

Public CMS NADAC pricing for Ganciclovir Ophthalmic is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Ganciclovir Ophthalmic currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Ganciclovir Ophthalmic in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Ganciclovir Ophthalmic approved by the FDA?

The FDA record lists the approval date for Ganciclovir Ophthalmic as 2016-12-06.

Who makes Ganciclovir Ophthalmic?

The FDA label lists Endo USA, Inc. as a labeler/manufacturer of Ganciclovir Ophthalmic. Multiple firms may market generics of the same molecule.

How should Ganciclovir Ophthalmic be stored?

The FDA label states: "Storage Store at 15°C-25°C (59°F-77°F). Do not freeze." Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…